Product Description
Mechanisms of Action: XO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India | Japan
Approved Indications: None
Known Adverse Events: None
Company: Fuji Yakuhin
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Gout
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20242287 | P2 |
Recruiting |
Gout |
None |
|
| CTR20242609 | P2 |
Recruiting |
Gout |
None |